Myosin Therapeutics Receives FDA Clearance To Initiate First-in-Human Trial of MT-125 in Glioblastoma
UF startup Myosin Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted the company's Investigational New Drug (IND) application for MT-125.
